Clinical trials: Obesity or Overweight, open to volunteers
Diabetes Mellitus, Type 2, Liver Fibrosis
Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)
In the Netherlands, there are many people with cardiometabolic diseases. More than half of these people also have fatty liver. This is a build-up of fat in the liver (steatosis) and can lead to long-term scarring (fibrosis) and…
- Conditions
- Diabetes Mellitus, Type 2, Liver Fibrosis, Liver Steatoses, Hepatic Steatosis
- Trial name
- MEDFAST (NCT06845345)
- Testing
- early time restricted Mediterranean diet, Mysimba
- Where
- Netherlands
- Volunteers
- 70 people
- Sponsor
- Carmen Dietvorst
Obesity & Overweight, Coronary Heart Disease
Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
This multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the effect of mazdutide, a dual GLP-1/GCG receptor agonist, on coronary plaque progression assessed by coronary computed tomography angiography…
- Trial name
- NCT07657676
- Testing
- Mazdutide
- Where
- China
- Volunteers
- 116 people
- Sponsor
- China National Center for Cardiovascular Diseases
Mediterranean Diet, Overweight or Obese Adults
ENERGY2MOB STUDY: OBESITY MANAGEMENT IN BERGUEDÀ
Background: Obesity is a prevalent multifactorial disease worldwide and has become a significant public health concern. The latest data from the 2022 Catalonia Health Survey show that 56.2% of men and 43.7% of women are…
- Conditions
- Mediterranean Diet, Overweight or Obese Adults, Exercise Therapy, Cardiovascular Diseases
- Trial name
- ENERGY2MOB (NCT06988904)
- Testing
- Energy2MOB
- Where
- Spain
- Volunteers
- 136 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
COPD Exacerbation, Oxygen Toxicity
Influence of FreeO2 on Percentage of Time Within Oxygen Saturation Target Using Noninvasive Ventilation (NIV) and Continuous Positive Airway Pressure (CPAP) for Patients Admitted for AECOPD or Bariatric Surgery
The main objective is to evaluate the FreeO2 device combined with noninvasive respiratory support technique for COPD patients and postoperative bariatric surgery patients.
- Conditions
- COPD Exacerbation, Oxygen Toxicity, Abdominal Obesity, Surgery
- Trial name
- NCT04136717
- Testing
- Washout period, NIV - FreeO2, Nasal High flow Oxygen therapy - FreeO2
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- François Lellouche
Apnea, Sleep Disorders
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive…
- Conditions
- Apnea, Sleep Disorders, Overweight and/or Obesity
- Trial name
- NCT07823608
- Testing
- Berobenatide
- Where
- 6 sites in United States
- Volunteers
- 258 people
- Sponsor
- Pfizer
Obesity or Overweight
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
- Trial name
- SELENE 1 (NCT07784725)
- Testing
- AZD6234
- Where
- 212 sites in United States, Argentina and 14 more
- Volunteers
- 2,500 people
- Sponsor
- AstraZeneca
Obesity or Overweight, Weight-Related Comorbidity
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment.
- Conditions
- Obesity or Overweight, Weight-Related Comorbidity, With/Without Diabetes Mellitus, Type 2
- Trial name
- SELENE 3 (NCT07776509)
- Testing
- Lenbelintide
- Where
- 96 sites in United States, Argentina and 9 more
- Volunteers
- 500 people
- Sponsor
- AstraZeneca
Overweight and Obesity
CHOICE to AVOID or RESIST
This trials will formally test whether participants' active choice of self-regulatory strategies (AVOID or RESIST) leads to greater adherence to weight management strategies by comparing the CHOICE arms to the randomized arms of…
- Trial name
- NCT06521021
- Testing
- AVOID, RESIST
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Overweight or Obesity
NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks
The goal of this clinical trial is to test an enhanced version of the National Diabetes Prevention Program (NDPP-NextGen) that is tailored to young women in childbearing years.
- Trial name
- NCT05674799
- Testing
- NDPP-NextGen
- Where
- United States
- Volunteers
- 403 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Type 1 Diabetes Mellitus, Overweight and Obesity
Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity
This study is a 2-arm, double blinded, randomised clinical trial where 40 participants will be assigned 1:1 to insulin treatment alone (control) or insulin treatment and tirzepatide treatment for 32 weeks.
- Trial name
- TZP-T1D (NCT06180616)
- Testing
- Tirzepatide
- Volunteers
- 40 people
- Sponsor
- Royal North Shore Hospital
Obesity, Overweight
Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily…
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Trial name
- NCT07654361
- Testing
- Aleniglipron
- Where
- 71 sites in United States
- Volunteers
- 3,600 people
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Obesity
A Phase I Study of Single and Multiple Doses of HS-20136-2 Injection in Healthy or Obese Participants
The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HS-20136-2 injection in healthy/obese participants.
- Trial name
- NCT07716241
- Testing
- HS-20136-2
- Where
- China
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Overweight, Obesity
A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity
The main purpose of the study is to measure and compare the effects of eloralintide and placebo on insulin sensitivity (how your body responds to insulin), metabolic health (things like sugar and cholesterol), and body weight in…
- Trial name
- NCT07665879
- Testing
- Eloralintide
- Where
- 2 sites in Germany, Sweden
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obese or Overweight Healthy Volunteers
Clinical Study to Assess the Safety and Efficacy of ACV Moringa Effervescent Tablet Intake on Weight Management in Overweight and Class I Obese Study Participants
A Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Single-Centre, Clinical Study to Evaluate the Safety and Efficacy of Intake of ACV Moringa on the Degree of Weight Change in Overweight and Class I Obese Study Participants
- Trial name
- NCT07098624
- Testing
- ACV Moringa Effervescent Tablets 4.3 g
- Volunteers
- 66 people
- Sponsor
- NovoBliss Research Pvt Ltd
Overweight or Obesity
Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes.
To evaluate the efficacy and safety of SYH2069 injection compared with placebo in obese Non-diabetic Participants after 28 weeks of treatment.
- Trial name
- NCT07803991
- Testing
- SYH2069 Injection
- Where
- China
- Volunteers
- 360 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Obesity
Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM)
This is a prospective, multicenter, real-world study conducted in Bangladesh to assess the effectiveness and safety of Tirzepatide compared to structured lifestyle interventions, including dietary modifications and exercise, in…
- Trial name
- NCT07099742
- Testing
- Tirzepatide, Life Style Modification
- Where
- 3 sites in Bangladesh
- Volunteers
- 364 people
- Sponsor
- Dr. Md. Alimur Reza
Healthy Participants, Obesity
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or…
- Trial name
- NCT07511205
- Testing
- AZD1043
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Overweight or Obese
A Study to Evaluate MWN109 Injection in Healthy Subjects
This study is a Phase1, randomized, double-blinded, and placebo-controlled study. In each cohort, enrolled participants will be randomized to receive either placebo or MWN109.
- Trial name
- NCT06859853
- Testing
- Subcutaneous single and mutiple dose
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obesity/Overweight in Adult
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
This study is a multicenter, randomized, open-label, parallel-group phase III clinical trial comparing the efficacy and safety of GZR18 Injection and semaglutide (Wegovy®) in adult obese or overweight subjects, aiming to evaluate…
- Trial name
- NCT07150975
- Testing
- GZR18, Semaglutide(Wegovy® )
- Where
- China
- Volunteers
- 420 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Overweight or Obesity; Type 2 Diabetes, Weight Loss Maintenance
AI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)
This is a randomized controlled trial to compare the effect of AI-assisted multi-domain lifestyle and continued tirzepatide on body weight loss maintenance.
- Trial name
- NCT07555730
- Testing
- AI assisted multi-domain lifestyle intervention, Tirzepatide
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Huazhong University of Science and Technology